Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Immix Biopharma director Jane Buchan reported equity compensation awards. She received 6,250 restricted stock units of common stock, bringing her direct common stock holdings to 28,705 shares after the grant.
She was also granted options to buy 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. The RSUs vest in full on the earlier of one year from grant or the 2027 annual meeting, while the options vest in substantially equal monthly installments over 12 months, with any remaining portion vesting at the 2027 annual meeting, in each case subject to continued service.
Immix Biopharma, Inc. is raising capital through an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, for expected gross proceeds of $150 million and estimated net proceeds of about $140.65 million. The deal is being led by Morgan Stanley under an existing shelf registration statement and is expected to close around May 22, 2026, subject to customary conditions. Immix plans to use the cash mainly to fund development of its BCMA-targeted CAR-T therapy NXC-201, as well as for working capital and general corporate purposes, and believes this financing, together with existing cash, will fund operations into mid-2028.
Immix Biopharma, Inc. is raising capital through an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, for expected gross proceeds of $150 million and estimated net proceeds of about $140.65 million. The deal is being led by Morgan Stanley under an existing shelf registration statement and is expected to close around May 22, 2026, subject to customary conditions. Immix plans to use the cash mainly to fund development of its BCMA-targeted CAR-T therapy NXC-201, as well as for working capital and general corporate purposes, and believes this financing, together with existing cash, will fund operations into mid-2028.
Immix Biopharma is offering 16,778,524 shares of common stock at $8.94 per share. The prospectus supplement states net proceeds are estimated at approximately $140.65 million to fund NXC-201 clinical development, working capital and general corporate purposes. Shares outstanding immediately after the offering are shown as 69,790,616.
The filing notes clinical progress for CAR-T candidate NXC-201, including a reported 95% CR rate (19/20) among an early cohort in NEXICART-2 and regulatory designations such as RMAT, ODD and Breakthrough Therapy. Management retains broad discretion over use of proceeds and lock-up and stabilization arrangements are described.
Immix Biopharma is offering 16,778,524 shares of common stock at $8.94 per share. The prospectus supplement states net proceeds are estimated at approximately $140.65 million to fund NXC-201 clinical development, working capital and general corporate purposes. Shares outstanding immediately after the offering are shown as 69,790,616.
The filing notes clinical progress for CAR-T candidate NXC-201, including a reported 95% CR rate (19/20) among an early cohort in NEXICART-2 and regulatory designations such as RMAT, ODD and Breakthrough Therapy. Management retains broad discretion over use of proceeds and lock-up and stabilization arrangements are described.
Immix Biopharma reported interim Phase 2 NEXICART-2 data showing a 95% complete response (CR) rate, with 19 of the first 20 relapsed/refractory AL amyloidosis patients treated with CAR-T candidate NXC-201 achieving CR.
All minimal residual disease (MRD)-negative patients converted to CR, and all CRs occurred within one year of follow-up, with no relapses observed so far among CR patients. Seventeen of 20 patients showed rapid normalization of diseased light chains, with a median time to initial response of 7 days, and MRD-negativity at 10-5 was reached within 30 days for all MRD-negative patients.
NEXICART-2 is a fully enrolled 45-patient, multi-site U.S. Phase 2 trial with a potentially registrational design, and the next data update is expected in late September 2026. The company also plans a multi-center, randomized Phase 3 trial in newly diagnosed AL amyloidosis patients, targeted to start in the first half of 2027.
Immix Biopharma reported interim Phase 2 NEXICART-2 data showing a 95% complete response (CR) rate, with 19 of the first 20 relapsed/refractory AL amyloidosis patients treated with CAR-T candidate NXC-201 achieving CR.
All minimal residual disease (MRD)-negative patients converted to CR, and all CRs occurred within one year of follow-up, with no relapses observed so far among CR patients. Seventeen of 20 patients showed rapid normalization of diseased light chains, with a median time to initial response of 7 days, and MRD-negativity at 10-5 was reached within 30 days for all MRD-negative patients.
NEXICART-2 is a fully enrolled 45-patient, multi-site U.S. Phase 2 trial with a potentially registrational design, and the next data update is expected in late September 2026. The company also plans a multi-center, randomized Phase 3 trial in newly diagnosed AL amyloidosis patients, targeted to start in the first half of 2027.
Janus Henderson Group plc reported beneficial ownership of 4,802,002 shares of Immix Biopharma, Inc. common stock, representing 9.1% of the class as disclosed on this Schedule 13G/A. The filing states the shares are held through multiple asset managers that exercise shared voting and dispositive power on behalf of managed portfolios.
The filing notes that the managed portfolios are the record holders entitled to dividends and sale proceeds, and that only Janus Henderson Biotech Innovation Master Fund Ltd. holds more than 5% with dividend/proceeds rights. The reporting person disclaims rights to receive dividends or sale proceeds for the asset managers described.
Immix Biopharma, Inc. reported a larger net loss as it continues to invest heavily in its cell therapy pipeline. For the three months ended March 31, 2026, net loss was $10.1 million, compared with $4.5 million a year earlier, driven by higher research and development and general and administrative expenses totaling $10.8 million.
Cash, cash equivalents and short-term investments were $90.6 million as of March 31, 2026, and total stockholders’ equity was $84.4 million. The company states this liquidity should fund operating and capital needs for at least 12 months from the filing of the quarterly report while it advances NXC‑201 and other programs.
Immix Biopharma, Inc. Schedule 13G/A amendment shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 1,750,200 shares of Common Stock (CUSIP 45258H106), representing 3.3% of the class as disclosed on the cover pages. The filing states the shares are held by entities subject to voting and investment discretion of Millennium Management LLC and/or other managers affiliated with Millennium Group Management LLC and Mr. Englander and includes a Joint Filing Agreement dated May 1, 2026.
Immix Biopharma, Inc. is asking stockholders to elect nine directors and ratify its auditor at the 2026 annual meeting. The meeting is scheduled for May 22, 2026 in Los Angeles, with a March 31, 2026 record date and 53,012,092 common shares entitled to one vote each.
The proposed slate includes CEO and Chairman Ilya Rachman, CFO and President Gabriel Morris, and seven independent or non-executive directors with scientific, financial, legal and industry backgrounds. Stockholders will also vote on ratifying Crowe LLP as independent registered public accounting firm for the year ending December 31, 2026.
The company highlights that six of nine directors are Nasdaq-independent, maintains audit, compensation, and nominating/governance committees, and uses a 2021 omnibus equity incentive plan. For 2025, CEO and CFO base salaries were $475,000 each, with cash bonuses and option grants linked to clinical, operational, and financing milestones.
Immix Biopharma announced that enrollment is complete in its BLA-enabling NEXICART-2 Phase 2 trial of CAR‑T therapy NXC‑201 for relapsed/refractory AL amyloidosis, a 40‑patient U.S. study. The company expects topline NEXICART‑2 results in Q3 2026, followed by a planned biologics license application submission and potential commercial launch.
NXC‑201 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Orphan Drug designations in the U.S., and Orphan status in the EU. Immix also onboarded a commercially experienced Chief Medical Officer with prior leadership roles at Merck and Johnson & Johnson to help prepare for the anticipated regulatory filing.